Vaxxas has received a manufacturing licence from Australia’s Therapeutic Goods Administration (TGA) for its high-density microarray patch (HD-MAP) for clinical studies at a biomedical facility in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback